285 related articles for article (PubMed ID: 23715576)
1. Prediction of response to anticancer immunotherapy using gene signatures.
Wang E; Bedognetti D; Marincola FM
J Clin Oncol; 2013 Jul; 31(19):2369-71. PubMed ID: 23715576
[No Abstract] [Full Text] [Related]
2. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
[TBL] [Abstract][Full Text] [Related]
4. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
[TBL] [Abstract][Full Text] [Related]
5. Melanoma vaccines: mixed past, promising future.
Ozao-Choy J; Lee DJ; Faries MB
Surg Clin North Am; 2014 Oct; 94(5):1017-30, viii. PubMed ID: 25245965
[TBL] [Abstract][Full Text] [Related]
6. Are vaccines making a comeback in non-small-cell lung cancer?
Nemunaitis JJ
J Clin Oncol; 2008 Mar; 26(9):1402-3. PubMed ID: 18349390
[No Abstract] [Full Text] [Related]
7. [Molecular biology of lung cancer series].
Hiret S; Senellart H; Bennouna J
Rev Mal Respir; 2010 Oct; 27(8):954-8. PubMed ID: 20965409
[TBL] [Abstract][Full Text] [Related]
8. Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer.
Adam V; Wauters I; Vansteenkiste J
Expert Opin Biol Ther; 2014 Mar; 14(3):365-76. PubMed ID: 24456101
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Frydenlund N; Mahalingam M
Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
[TBL] [Abstract][Full Text] [Related]
10. Pseudoprogression and Immune-Related Response in Solid Tumors.
Chiou VL; Burotto M
J Clin Oncol; 2015 Nov; 33(31):3541-3. PubMed ID: 26261262
[No Abstract] [Full Text] [Related]
11. Update on active specific immunotherapy with melanoma vaccines.
Conforti AM; Ollila DW; Kelley MC; Gammon G; Morton DL
J Surg Oncol; 1997 Sep; 66(1):55-64. PubMed ID: 9290695
[TBL] [Abstract][Full Text] [Related]
12. [Vaccines for the treatment of non-small cell lung cancer].
Leduc C; Quoix E
Rev Mal Respir; 2019 Mar; 36(3):415-425. PubMed ID: 30902445
[TBL] [Abstract][Full Text] [Related]
13. [Long-term remission of malignant melanoma stage IV after antigen-specific immunotherapy].
Neumann A; Karbach J; Atmaca A; Jäger E
Med Klin (Munich); 2010 Apr; 105(4):273-5. PubMed ID: 20455048
[TBL] [Abstract][Full Text] [Related]
14. Lung cancer: potential targets for immunotherapy.
Tartour E; Zitvogel L
Lancet Respir Med; 2013 Sep; 1(7):551-63. PubMed ID: 24461616
[TBL] [Abstract][Full Text] [Related]
15. Vaccination and melanoma risk.
Pfahlberg A; Botev IN; Kölmel KF; Gefeller O
Int J Cancer; 2002 Nov; 102(1):96-7. PubMed ID: 12353240
[No Abstract] [Full Text] [Related]
16. Current status of immunotherapy.
Suzuki S; Ishida T; Yoshikawa K; Ueda R
Jpn J Clin Oncol; 2016 Mar; 46(3):191-203. PubMed ID: 26819277
[TBL] [Abstract][Full Text] [Related]
17. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
Wieckowski S; Baumgaertner P; Corthesy P; Voelter V; Romero P; Speiser DE; Rufer N
J Immunol; 2009 Oct; 183(8):5397-406. PubMed ID: 19786555
[TBL] [Abstract][Full Text] [Related]
18. Melanoma treatment's changing landscape.
Jenks S
J Natl Cancer Inst; 2014 Jun; 106(6):dju176. PubMed ID: 24907389
[No Abstract] [Full Text] [Related]
19. PD-L1 expression as a potential predictive biomarker.
Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
Lancet Oncol; 2015 Oct; 16(13):1285-7. PubMed ID: 26433815
[No Abstract] [Full Text] [Related]
20. Melanoma vaccine momentum spurs interest, investment.
Fintor L
J Natl Cancer Inst; 2000 Aug; 92(15):1205-7. PubMed ID: 10922403
[No Abstract] [Full Text] [Related]
[Next] [New Search]